Titan Pharmaceuticals, Inc .

TITAN PHARMACEUTICALS ANNOUNCES UPLISTING

SAN FRANCISCO, CA - Oct. 8, 2015 - Titan Pharmaceuticals, Inc. (OTCQB: TTNPD), a specialty pharmaceutical

company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura long-term,

continuous drug delivery technology, announced today that it has received approval to list its common stock on the NASDAQ Capital

Market effective at the opening of trading on Monday, Oct.12, 2015. The company's stock will trade under the symbol TTNP.

"Uplisting to the NASDAQ Capital Market comes at an important

time of growth for Titan, as we await potential approval of Probuphine in the first quarter of next year and expand our pipeline

of product candidates based on our ProNeura long-term, continuous drug delivery technology," said Titan President Sunil Bhonsle.

"As a company listed on NASDAQ, Titan will gain greater visibility across a broader range of professional and institutional

investors, and potentially generate more value for all of our shareholders."

Before trading on NASDAQ commences, Titan's common stock

will continue to be quoted on the OTCQB under the symbol TTNPD.

About Titan Pharmaceuticals

Titan Pharmaceuticals Inc. (OTCQB: TTNPD), based in South San

Francisco, CA, is a specialty pharmaceutical company developing proprietary therapeutics primarily for the treatment of serious

medical disorders. The company's lead product candidate is Probuphine , a novel and long-acting formulation of buprenorphine

for the long-term maintenance treatment of opioid dependence. Probuphine employs Titan's proprietary drug delivery system

ProNeura , which is capable of delivering sustained, consistent levels of medication for three months or longer. Titan has

granted U.S. and Canadian commercial rights for Probuphine to Braeburn Pharmaceuticals. If approved, Probuphine would be the first

and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for

six months following a single procedure. The ProNeura technology has the potential to be used in developing products for treating

other chronic conditions, such as Parkinson's disease, where maintaining consistent blood levels of a therapeutic agent

may benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com.

This press release may contain "forward-looking statements"

within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements

include, but are not limited to, any statements relating to our product development programs and any other statements that are

not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results,

financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations

include those risks and uncertainties relating to the regulatory approval process, the development, testing, production and marketing

of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly

disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained

herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement

is based, except as required by law.

Titan Pharmaceuticals, Inc.:

Sunil Bhonsle, President